{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:37:06Z","timestamp":1792705026594,"version":"4.5.0"},"reference-count":30,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Microsatellite instability-high (MSI-H) colon cancer with isolated peritoneal metastases (iPM) represents a molecularly and anatomically distinct clinical subset with limited evidence to guide treatment. Given the unique immunogenic profile of MSI-H tumors and the historically poor prognosis of peritoneal dissemination, we evaluated the association of immunotherapy, chemotherapy, and surgery with survival outcomes in this population. Methods: Using the National Cancer Database, we identified patients with MSI-H colon cancer and iPM diagnosed between 2016\u20132021. Patients were stratified by systemic therapy type (immunotherapy, chemotherapy, combination) and surgical resection status. Kaplan\u2013Meier and multivariable Cox regression analyses were used to assess overall survival (OS). Results: Among 598 patients, 22% received systemic treatment with immunotherapy and 76% underwent surgical resection. Immunotherapy was associated with significantly longer median OS compared to chemotherapy (33 vs. 18 months, p &lt; 0.001). On multivariable analysis, immunotherapy remained independently associated with improved survival (HR: 0.46; p &lt; 0.001). Surgical resection of the primary tumor with (HR: 0.40; p &lt; 0.001) or without metastatectomy (HR: 0.41; p &lt; 0.001) was associated with longer survival, and the combination of surgery and immunotherapy yielded the greatest survival benefit. Conclusions: Patients with MSI-H colon cancer and iPM treated with immunotherapy had significantly improved survival, compared to chemotherapy. Surgical resection combined with immunotherapy is associated with the greatest survival benefit, supporting a multimodal approach. These findings provide real-world evidence supporting integration of immunotherapy and surgery in this molecularly and anatomically distinct population.<\/jats:p>","DOI":"10.3390\/cancers17213496","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:33:07Z","timestamp":1761881587000},"page":"3496","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunotherapy Plus Surgery Improves Survival in Microsatellite Instability-High Colon Cancer with Isolated Peritoneal Metastases"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4812-8332","authenticated-orcid":false,"given":"Daniel Aryeh","family":"Metzger","sequence":"first","affiliation":[{"name":"New York-Presbyterian\u2014Weill Cornell, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmeen","family":"Chahal","sequence":"additional","affiliation":[{"name":"New York-Presbyterian\u2014Weill Cornell, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Watman","sequence":"additional","affiliation":[{"name":"New York-Presbyterian\u2014Brooklyn Methodist Hospital, Brooklyn, NY 11215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5429-0080","authenticated-orcid":false,"given":"Ying","family":"Li","sequence":"additional","affiliation":[{"name":"New York-Presbyterian\u2014Weill Cornell, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Pigazzi","sequence":"additional","affiliation":[{"name":"City of Hope Orange County Lennar Foundation Cancer Center, Irvine, CA 92618, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3756-6038","authenticated-orcid":false,"given":"Despina","family":"Siolas","sequence":"additional","affiliation":[{"name":"New York-Presbyterian\u2014Weill Cornell, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehraneh D.","family":"Jafari","sequence":"additional","affiliation":[{"name":"New York-Presbyterian\u2014Weill Cornell, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/bjs.8679","article-title":"Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer","volume":"99","author":"Segelman","year":"2012","journal-title":"Br. J. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Elias","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6604867","article-title":"Deficient mismatch repair system in patients with sporadic advanced colorectal cancer","volume":"100","author":"Koopman","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2479527","DOI":"10.1080\/02656736.2025.2479527","article-title":"Impact of RAS, BRAF mutations and microsatellite status in peritoneal metastases from colorectal cancer treated with cytoreduction \u2009+\u2009 HIPEC: Scoping review","volume":"42","author":"Zucchini","year":"2025","journal-title":"Int. J. Hyperth."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: A pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e14576","DOI":"10.1200\/JCO.2023.41.16_suppl.e14576","article-title":"Outcomes of peritoneal metastases in mismatch repair deficient (dMMR) cancers treated with immune checkpoint inhibitors and variables associated with response","volume":"41","author":"Mosalem","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_7","unstructured":"(2024, March 08). National Comprehensive Cancer Network Colon Cancer. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20180102","DOI":"10.1515\/pp-2018-0102","article-title":"Therapeutic efficacy of systemic therapy for colorectal peritoneal carcinomatosis: Surgeon\u2019s perspective","volume":"3","author":"Franko","year":"2018","journal-title":"Pleura Peritoneum"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","article-title":"Peritoneal-Plasma Barrier","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat. Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Rietveld, P.C.S., Guchelaar, N.A.D., van Eerden, R.A.G., de Boer, N.L., de Bruijn, P., Sassen, S.D.T., Madsen, E.V.E., Koch, B.C.P., Verhoef, C., and Burger, J.W.A. (2024). Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5-fluorouracil and bevacizumab in patients with colorectal peritoneal metastases. Biomed. Pharmacother., 176.","DOI":"10.1016\/j.biopha.2024.116820"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability\u2013High Advanced Colorectal Cancer","volume":"383","author":"Shiu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1245\/s10434-020-08733-x","article-title":"Metastatic Colorectal Cancers with Mismatch Repair Deficiency Result in Worse Survival Regardless of Peritoneal Metastases","volume":"27","author":"Sherman","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"230400","DOI":"10.1001\/jamanetworkopen.2023.0400","article-title":"Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab + Supplemental content","volume":"6","author":"Jones","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.dld.2022.09.015","article-title":"Immune checkpoint inhibitors for patients with isolated peritoneal carcinomatosis from dMMR\/MSI-H colorectal cancer, a BIG-RENAPE collaboration","volume":"55","author":"Barraud","year":"2023","journal-title":"Dig. Liver Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Hallam, S., Stockton, J., Bryer, C., Whalley, C., Pestinger, V., Youssef, H., and Beggs, A.D. (2020). The transition from primary colorectal cancer to isolated peritoneal malignancy is associated with an increased tumour mutational burden. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-75844-6"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/cas.70021","article-title":"Cell Biology of Cancer Peritoneal Metastasis: Multiclonal Seeding and Peritoneal Tumor Microenvironment","volume":"116","author":"Yamaguchi","year":"2025","journal-title":"Cancer Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-022-01828-7","article-title":"Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies","volume":"83","author":"Guchelaar","year":"2023","journal-title":"Drugs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1245\/s10434-022-13025-7","article-title":"PD-1 Blockade Combined with Heated Intraperitoneal Chemotherapy Improves Outcome in Experimental Peritoneal Metastases from Colonic Origin in a Murine Model","volume":"30","author":"Geva","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Xia, W., Geng, Y., and Hu, W. (2023). Peritoneal Metastasis: A Dilemma and Challenge in the Treatment of Metastatic Colorectal Cancer. Cancers, 15.","DOI":"10.3390\/cancers15235641"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1001\/jamasurg.2021.1642","article-title":"Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial","volume":"156","author":"Rovers","year":"2021","journal-title":"JAMA Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1245\/s10434-023-13116-z","article-title":"Perioperative Systemic Therapy Versus Cytoreductive Surgery and HIPEC Alone for Resectable Colorectal Peritoneal Metastases: Patient-Reported Outcomes of a Randomized Phase II Trial","volume":"30","author":"Bakkers","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41416-021-01620-6","article-title":"Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients","volume":"126","author":"Larsen","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.gassur.2024.06.019","article-title":"Microsatellite instability should not determine candidacy for cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion in patients with peritoneal metastases from colorectal cancer","volume":"28","author":"Ruff","year":"2024","journal-title":"J. Gastrointest. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.2024.42.3_suppl.117","article-title":"Neoadjuvant botensilimab plus balstilimab in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial","volume":"42","author":"Kasi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair\u2013Deficient Colon Cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"LBA1","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1","article-title":"Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC)","volume":"43","author":"Sinicrope","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e2252244","DOI":"10.1001\/jamanetworkopen.2022.52244","article-title":"Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients with Metastatic Colorectal Cancer with Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden","volume":"6","author":"Quintanilha","year":"2023","journal-title":"JAMA Netw. Open"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3496\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:52:24Z","timestamp":1761882744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":30,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cancers17213496"],"URL":"https:\/\/doi.org\/10.3390\/cancers17213496","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]}}}